Guest edited by Dr. Felice Gragnano, Dr. Arturo Cesaro, and Prof. Paolo Calabrò from the University of Campania “Luigi Vanvitelli”, Caserta, Italy
Lipids in Health and Disease invites you to contribute a manuscript to our new thematic series, "Targeting Lipids for Cardiovascular Health: Novel Mechanisms and Therapeutics".
People who maintain ideal cardiovascular health have high life expectancy and low lifetime risk of disabling and life-threatening medical conditions. Therefore, the identification and adoption of novel strategies to pursue ideal cardiovascular health represent a vital opportunity to improve the prevention and treatment of cardiovascular diseases. Because atherogenic lipids and lipoproteins play a causal role in the initiation and progression of endothelial dysfunction and atherosclerosis, maintenance of optimal lipid levels is necessary to attain ideal cardiovascular health status.
Evidence from Mendelian randomization studies and randomized trials has conclusively demonstrated that lower low-density lipoprotein cholesterol (LDL-C) can effectively reduce cardiovascular risks. Additional benefits may derive from lowering triglycerides and lipoprotein(a) and elevating serum levels and activity of high-density lipoprotein cholesterol (HDL-C).
To date, numerous challenges and controversies exist concerning the cumulative effect of lipid-carrying lipoproteins on cardiovascular health, the magnitude of the clinical benefit obtained by achieving and maintaining optimal lipid levels and the best timing to initiate lipid-modifying strategies to mitigate cardiovascular risk.
We invite you to contribute to this new thematic series of Lipids in Health and Disease, which will focus on the link between lipids and cardiovascular health from mechanisms to therapeutics, emphasizing the importance of an individualized approach in clinical and preclinical studies design (so-called “precision medicine”).
We warmly welcome articles, including original research, narrative reviews, systematic reviews and meta-analyses, mini-reviews, and commentary on this relevant and rapidly evolving topic.
Lipids, lipoproteins, LDL, HDL, lipoprotein(a), triglycerides, atherosclerosis, endothelial dysfunction, cardiovascular disease, cardiometabolic disease.
All submissions should be made by 31 December 2023.
- Mechanisms and molecular pathways affecting lipids and lipoproteins metabolism
- Impact of genetics on lipid and metabolic disorders
- Effect of lipid-lowering therapy on cardiovascular health
- Lipid targets in cardiovascular disease
- Future perspective and novel therapeutic strategies in dyslipidemias
Questions to be answered:
- What are the novel mechanisms involved in the regulation of lipid metabolism?
- Can genetic evaluation guide decision-making in the management of lipid disorders?
- Should lipid targets be individualized according to patient risk profile?
- What is the mechanistic link between cholesterol and triglyceride disorders?
- How do non-LDL cholesterol targets affect clinicians’ decisions in contemporary practice?
- What are the following steps to be taken to reduce the residual cardiovascular burden?
This collection of articles has not been sponsored and articles have undergone the journal’s standard peer-review process.